Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia

Inclusion Criteria: 1. Male and female between the ages of 20-75 years. 2. Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control. 3. Diagnosed with type 2 diabetes mellitus. 4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL 5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable). 6. All patients give written informed consent. Exclusion Criteria: 1. A history of hypersensitivity to statins. 2. A history of rhabdomyolysis or hereditary muscle disorders. 3. Insulin-treated patients. 4. Patient with any conditions of acute or chronic pancreatitis. 5. Creatine kinase ≧3-fold upper limit of normal (ULN). 6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1.5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT ≧3-fold ULN). 7. Overt proteinuria (repeat spot urine protein \>300mg/dl by dipstick method). 8. Patients are taking cyclosporine. 9. A history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia. 10. Patients with alcohol and drug abuse in past 3 years. 11. Serious or unstable medical or psychological conditions. 12. Hypothyroidism (TSH \> 5 μIU/mL). 13. In the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial.